
2026-04-08
Kutanga kurapwa kwegomarara remapapu muna 2026 kunoreva kupindira kwekurapa kwepamusoro kunoshandiswa kuona uye kubata cancer yemapapu pamatanho ayo ekutanga, zvakanyanya kuvandudza huwandu hwekupona. Nzira dzazvino muChina uye pasi rose dzinobatanidza hungwaru hwekugadzira (AI) hwekukurumidza kuonekwa, nzira dzekuvhiya chaidzo, marapirwo anonangwa, uye immunotherapy. Varwere vachitsvaga kurapwa kenza yemapapu ekutanga ikozvino vanokwanisa kuwana zvirongwa zvekuongorora zvinodhura, senge AI-enhanced CT scans inowanikwa muzvipatara zvikuru zveChinese zvemadhora makumi maviri nemashanu, pamwe chete nemishonga yekurapa inogadzirisa munhu kutarisisa zvichienderana nemajini profiles.
Chirwere chegomarara chemapapu chinoramba chiri chikonzero chikuru chekufa kwakabatana negomarara pasi rese, asi mamiriro e kurapwa kenza yemapapu ekutanga yakashandura zvakanyanya ne 2026. Kuchinja kubva kune imwe-saizi-inokodzera-yese nzira yekurapa chaiyo yakatsanangurazve mhedzisiro yevarwere. Kukurumidza kuvhenekwa iko zvino ndiyo nheyo yekurapa kwakabudirira, nehunyanzvi hutsva hunoita kuti vanachiremba vaone mapundu zviratidzo zvisati zvaoneka.
Tsanangudzo yekenza yemapapu yepakutanga inowanzo sanganisira Stage I uye Stage II isiri-diki yekenza yemapapu (NSCLC), uko bundu rinowanikwa munzvimbo uye harina kupararira kune nhengo dziri kure. Muna 2026, chinotariswa hachisi chekubvisa bundu chete asi pakudzivirira kudzoka kuburikidza neadjuvant marapirwo akagadzirirwa kumurwere chaiwo genetic mutations.
Kufambira mberi kwazvino kwaita kuti zvikwanisike kurapa kenza yemapapu sechirwere chisingaperi pane kurwara kunouraya kuvarwere vazhinji. Kubatanidzwa kwe AI-inofambiswa diagnostics uye kuvhiyiwa kusingaite zvishoma yakaderedza nguva dzekupora uye yakavandudza hupenyu hwehupenyu mushure mekurapa.
Imwe yezvakanyanya kukosha muna 2026 kutorwa kwakapararira kweAI modhi muradiology. Aya masisitimu anoongorora yakajairwa yakaderera-dose computed tomography (LDCT) inoongorora nekurongeka kusati kwamboitika, ichizivisa mafundo akajeka anogona kupotsa maziso emunhu.
MuChina, zvipatara zvakaita seNingbo University Affiliated Hospital zvakatumira maAI mhando dzakagadzirwa nemasangano ekutsvagisa akadai seDAMO Academy. Aya mamodheru akaongorora mazana ezviuru zve CT scans, akabudirira mureza wekutanga-nhanho pancreatic nekenza yemapapu muvarwere vakaratidza zviratidzo zvisina hukama.
Iyi tekinoroji inonyanya kukosha kugomarara remapapu, uko huwandu hwemakore mashanu hwekupona hunosvetuka kubva pasi pegumi muzana mumatanho ekupedzisira kusvika pamusoro pe70% kana yaonekwa nekukurumidza. Kugona kuita zviratidziro izvi nechidimbu chemutengo wechinyakare - dzimwe nguva wakaderera semadhora makumi maviri nemashanu muzvirongwa zvekutyaira - kwamutsa kufarira kwepasirese kutora mhando dzakafanana.
China yakabuda senzvimbo yepasirese yekutarisira kenza yemapapu, kusanganisa huwandu hwevarwere nekukurumidza kutorwa kwehunyanzvi. Masangano akati wandei ari kutungamira mukuita izvi kurapwa kenza yemapapu ekutanga, inopa zvivakwa zvepasi rose uye tsvakiridzo yekutanga.
Iri muShanghai, chipatara ichi chiri epicenter yekutsvaga cancer yemapapu uye kurapwa. Nguva pfupi yadarika yakatanga iyo "2026 CACA Lung Cancer Yakazara-Domain Yakakurumbira Sayenzi Chiito," ichivavarira kuunza dziviriro, kuongororwa, kuongororwa, kurapwa, uye pfungwa dzekuvandudza kune veruzhinji.
Bazi rinoona nezvezvirwere muchipatara ichi, richitungamirwa nenyanzvi dzine mukurumbira saProfessor Zhou Caicun, rinosimbisa kuti gomarara remapapu hachisiri chirwere chimwe chete asi kuti iboka rezvirwere zvinotsanangurwa nemhando dzemutyairi dzakasiyana. Uzivi uhwu hunofambisa maprotocol avo ekurapa emunhu.
Sechipatara chikuru chechirwere chegomarara, Fudan University Shanghai Cancer Center iri pamberi pekugadzirwa kwekuvhiya uye miedzo yekiriniki. Iyo institution inoita basa rakakosha mukuvandudza nhungamiro yenyika, kusanganisira iyo "Little Red Book" yekutarisira kenza yemazamu nemapapu.
Nzvimbo iyi inozivikanwa nekuomerera kwayo kumishonga yakavakirwa pauchapupu uku ichikurumidza kubatanidza mishonga mitsva yekurapa mukuita kwekiriniki. Zvikwata zvavo zvakasiyana-siyana zvinoona kuti murwere wese anowana ongororo yakazara inosanganisira machiremba ekuvhiya, oncologists yekurapa, uye radiologists.
Kuwana kutariswa kwepasirese, chipatara ichi chinoratidza simba reAI mukutarisira kwemazuva ese. Inoshanda senzvimbo yekutyaira yeDAMO PANDA AI modhi, ichiratidza kuti tekinoroji inogona sei kuvhara mukaha pakati pekutarisirwa kwehunyanzvi uye kuongororwa kwehutano hwese.
Varwere vari pano vanobatsirwa kubva mukufambiswa kweseamless uko ziviso dzeAI dzinokonzeresa kuongororwa kwenyanzvi, kuve nechokwadi chekuti hapana zviratidzo zvekutanga zvehutsinye zvinoregeredzwa. Iyi modhi iri kudzokororwa muzvipatara zvakawanda zvenharaunda mudunhu rese.
Hunhu hwemari hwekuchengetedza hutano chinhu chakakosha kune varwere pasi rose. Muna 2026, chimiro chemutengo we kurapwa kenza yemapapu ekutanga inosiyana zvakanyanya zvichienderana nenyika, tekinoroji inoshandiswa, uye danho rekuonekwa.
Nzira dzechinyakare dzekuongorora munyika dzekuMadokero dzinogona kudhura zvisingaite, kazhinji dzichidhura mazana emadhora paCT scan imwe chete. Nekudaro, kubatanidzwa kweAI muChina kwakakanganisa iyi modhi.
Mapurogiramu ekutyaira anoshandisa AI-enhanced flat-scan CTs akadzikisa mitengo yekuongorora kusvika kunenge $25 USD. Uku kudzikiswa kwakanyanya kunowanikwa kuburikidza ne:
Kukwanisa uku kunoita kuti kuongororwa nguva dzose kugoneke kune huwandu hwevanhu, zvichikwanisa kushandura curve yekuongorora kuenda kumatanho ekutanga uko kurapwa kusinganyanyi kupindira uye kudhura.
Kunyange zvazvo kuongorora kwave kuchikwanisika, mari yekurapa kwechokwadi inobva pane yakasarudzwa nzira. Kuvhiya resection, chiyero chegoridhe chekutanga-danho kenza yemapapu, chinosanganisira kugara muchipatara, anesthesia, uye muripo wekuvhiya.
MuChina, mutengo wakazara wekuvhiyiwa kwevhidhiyo-kubatsirwa nethoracoscopic (VATS) inogona kubva pamadhora zviuru zvitatu kusvika kumadhora 8,000, yakaderera zvakanyanya pane inofananidzwa maitiro muUS kana Europe. Izvi zvinosanganisira pre-operative cheki uye post-operative care.
Kune varwere vanoda adjuvant therapy, mari yacho inosiyana zvichienderana nemishonga inoshandiswa. Traditional chemotherapy inowanzova isingadhuri, nepo mitsva inonangwa yekurapa uye immunotherapies inogona kudhura zvakanyanya. Nekudaro, zvirongwa zveinishuwarenzi yenyika uye mitemo yekutenga zvinhu zvakawanda muChina zvakadzikisa zvakanyanya mari yekubuda muhomwe yemishonga iyi yepamusoro.
| Chikamu | Inofungidzirwa Mutengo muChina (USD) | Inofungidzirwa Mutengo muUSA (USD) | Notes |
|---|---|---|---|
| AI-Yakawedzera LDCT Kuongorora | $25 - $60 | $300 - $800 | China inokwirisa AI yehuwandu hwekuongorora kunyatsoita. |
| VATS Surgery (Yekutanga Danho) | $3,000 - $8,000 | $20,000 - $50,000+ | Zvinosanganisira kugara muchipatara uye rubatsiro rwekutanga. |
| Targeted Therapy (Mwedzi wega wega) | $500 - $2,000 | $10,000 - $15,000 | Mitengo inosiyana zvichienderana nemishonga uye inishuwarenzi inodiwa. |
| Immunotherapy (Per Cycle) | $1,000 - $3,000 | $12,000 - $20,000 | Kutenga kwakawanda kunoderedza mitengo muChina. |
Tafura iyi inoratidza musiyano wakanyanya muhupfumi hwezvehutano. Kunyange mhando yekutarisira muzvipatara zveChinese zvepamusoro ichikwikwidza iyo yekuMadokero, mukana wemubhadharo unogadzira kurapwa kenza yemapapu ekutanga zviri nyore kusvikirwa nemugari wepakati.
Hondo yekurwisa cancer yemapapu yawedzera zvakanyanya. Muna 2026, kurapwa hakuchagumiri pakuvhiya uye chemotherapy. Mushonga wemishonga chaiwo unopa tariro kunyangwe nyaya dzakaoma kunzwisisa.
Kunzwisisa genetic makeup yebundu ikozvino chikamu chakajairwa chekuongorora. Vatyairi vakaita seEGFR, ALK, ROS1, uye KRAS vanoraira sarudzo yekurapa.
Chizvarwa chechitatu EGFR tyrosine kinase inhibitors (TKIs) ndiyo chiyero chekuchengetedza EGFR-mutated NSCLC. Zvisinei, kuramba kunoramba kuchikura. Zvichangoburwa zvinogadzirisa dambudziko iri zvakananga.
ADCs inomiririra shanduko yeparadigm mune oncology. Aya "mabhomba akangwara" anoendesa chemotherapy ine simba zvakananga kumasero egomarara, achichengetedza hutano hwakanaka. Muna 2026, maADC akanangana neTROP2 akaratidza kushanda kunoshamisa muvarwere vakafambira mberi paEGFR-TKIs.
Miedzo yemakiriniki, seyeOptiTROP-Lung04 ongororo inotungamirwa nevatsvagiri vekuChina, yakaratidza kuti TROP2-inotungamirwa ADCs inogona kuwedzera zvakanyanya kufambira mberi-kusununguka kupona kana kuchienzaniswa neyakajairwa chemotherapy. Izvi zvakamisa mwero mutsva wekutarisira nyaya dzisingachinji.
Immune checkpoint inhibitors (ICIs) inoramba ichinyanya kukosha, asi iyo inotevera wave inosanganisira bispecific antibodies iyo inobata immune system zvakanyanya. Mishonga iyi inogona kunanga maantigen maviri akasiyana panguva imwe chete, achiwedzera immune system kurwisa bundu.
Kune varwere vekutanga-danho, neoadjuvant immunotherapy (yakapihwa vasati vavhiyiwa) iri kuwana traction. Zvidzidzo zvinoratidza kuti nzira iyi inogona kuderedza mapundu, zvichiita kuti kuvhiyiwa kuve nyore uye kuderedza njodzi yekudzokazve.
Kunyangwe zvichiri kunyanya munzvimbo yemakiriniki ekuedzwa, marapirwo emasero senge CAR-T ari kuongororwa mamota akasimba anosanganisira cancer yemapapu. Pamusoro pezvo, majekiseni egomarara emunhu akagadzirirwa kumurwere akasarudzika neoantigens ari kuratidza chivimbiso mukudzivirira kudzokazve mushure mekuvhiyiwa.
Kufamba nehurongwa hwekuchengetedza hutano kunogona kunetsa. Kune vanotsvaka kurapwa kenza yemapapu ekutanga, kunyanya mumatunhu ane hunyanzvi hwepamberi senge China, kutevedzera nzira yakarongeka kunopa mhedzisiro yakanaka.
Iyi nzira yakarongeka inowedzera mikana yekurapa uye inoderedza kupindira kusingakoshi.
Kusarudza nzira yekurapa kwayo kunoda kunzwisisa zvakanakira nekuipira kwesarudzo dziripo. Pazasi pane kuenzanisa kwemaitiro ekutanga anoshandiswa muna 2026 ekutanga-danho remapapu cancer.
| Kurapa Maitiro | Hunhu Hunokosha | Ideal Candidates | Zvakanakira & Zvazvakaipira |
|---|---|---|---|
| Kuvhiya Kuvhiya (VATS/Robhoti) | Kubviswa kwemuviri kwebundu kuburikidza nemaitiro mashoma ekupinda. | Varwere vane Stage I-II NSCLC uye yakanaka mapapu basa. | Zvazvakanakira: Inogona kurapwa, kubvisa bundu nekukurumidza. Cons Njodzi dzekuvhiya, nguva yekudzorera, isina kukodzera kune varombo vanovhiya. |
| Targeted Therapy | Mishonga yemuromo inonangana nekuchinja kwemajini (semuenzaniso, EGFR, ALK). | Varwere vane kutaridzirwa kuchinja kwevatyairi; Kazhinji inoshandiswa seyemubatsiri kana neoadjuvant. | Zvazvakanakira: High efficacy, oral administration, shoma migumisiro pane chemo. Cons Resistance development nekufamba kwenguva, inoda genetic test. |
| Immunotherapy | Mishonga inowedzera immune system yekurwisa cancer. | Varwere vane yakakwira PD-L1 kutaura kana sechikamu chemusanganiswa kurapa. | Zvazvakanakira: Mhinduro dzinogara kwenguva refu, mukana wekuregererwa kwenguva refu. Cons Zviitiko zvakashata zvine chekuita nekudzivirira muviri, mazinga ekupindura akasiyana. |
| Antibody-Drug Conjugates (ADCs) | Zvinotarisirwa kuendesa chemotherapy agents kune cancer maseru. | Varwere vane chirwere chinopesana kana kuti chaiyo antigen kutaura (semuenzaniso, TROP2). | Zvazvakanakira: Precision kunanga, inoshanda mumatambudziko anopokana. Cons Yakananga toxicity profiles (semuenzaniso, neutropenia), inobuda data renguva refu. |
Kuenzanisa uku kunosimbisa kukosha kwemishonga yemunhu. Hapana imwe "yakanakisisa" kurapwa; sarudzo yakakwana zvinoenderana nehupenyu hwemunhu uye mamiriro ekiriniki.
Pasinei nekufambira mberi kunoshamisa, matambudziko achiripo mukurwisa kenza yemapapu. Kusiyana kwekuwana kurapwa kenza yemapapu ekutanga pakati pemadhorobha nemaruwa, uye pakati penyika dzakasiyana, imhinganidzo huru.
Nepo AI ichipa mhinduro, kupararira kwayo kwakapararira kunoda zvivakwa uye kudzidziswa. Matunhu mazhinji achiri kushaya zviwanikwa zvemakomputa kana vashandi vane hunyanzvi hwekududzira zvinobuda muAI nemazvo. Nhamburiko dziri kuitwa dzekurerutsa maturusi aya uye nekuabatanidza mumidziyo inotakurika yenzvimbo dziri kure.
Mishandirapamwe yekudzidzisa, senge yakatangwa neChina Anti-Cancer Association, yakakosha. Vane chinangwa chekusimudzira veruzhinji nezve kukosha kwekuvhenekwa uye kubvisa ngano dzakatenderedza kuongororwa kwegomarara.
Kusadzivirika kwekurwisa zvinodhaka kunoramba kuri mupikisi anotyisa. Vatsvaguri vari kugara vachitsvaga zvibodzwa zvitsva uye nzira dzekubatanidza kuti varambe vari pamberi pekubuda kwebundu clones. Tarisiro iri kuenda ku "adaptive therapy," uko kurapwa kunogadziriswa zvine simba zvichibva pane chaiyo-nguva yekutarisisa yekupindura bundu.
Iko kuunganidzwa kwehuwandu hukuru hwe data yekiriniki iri kutyaira inotevera wave yezviwanikwa. Humbowo hwepasirese (RWE) hunozadzisa zviyedzo zvakadzorwa nekupa ruzivo rwekuti marapirwo anoitwa sei munzvimbo dzakasiyana, dzemazuva ese. Iyi data inobatsira mukukwenenzvera nhungamiro uye optimize kurapa maprotocol.
Kuti uwedzere kubatsira vaverengi, heino mhinduro kumibvunzo yakajairika maererano kurapwa kenza yemapapu ekutanga mumamiriro ezvinhu ekurapa aripo.
Hongu, kenza yemapapu yepakutanga-tanga (Stage I neII) ine mwero wekurapa wakanyanya, kunyanya kana ichirapwa nekuvhiyiwa kuchiteverwa neakakodzera adjuvant therapy. Kupona kwemakore mashanu kweStage IA NSCLC kunogona kudarika 80-90% nemaitiro emazuva ano ekurapa.
Muzvirongwa zvekutyaira muChina, AI-inokwidziridzwa CT yekuongorora inogona kuita shoma semadhora makumi maviri nemashanu. Mune mamwe matunhu epasi, mitengo inosiyana zvakanyanya zvichienderana nehurongwa hwehutano, kuvharwa kweinishuwarenzi, uye tekinoroji chaiyo inoshandiswa. Kazhinji, inokwanisika kupfuura yechinyakare inodzokororwa kuongorora nekuda kwekunyanya kuita.
Maside effects anosiyana neboka rezvinodhaka. Mishonga inonangwa inowanzokonzera mapundu eganda, manyoka, kana kukwidziridzwa kweenzyme yechiropa. Immunotherapies inogona kutungamira kune zviitiko zvakashata zvine chekuita nemuviri zvinokanganisa mapapu, colon, kana endocrine glands. ADCs inogona kukonzera neutropenia kana kuneta. Mishonga mizhinji inogoneka nekutariswa kwakakodzera kwechiremba.
Hongu, zvipatara zvakawanda zvepamusoro-soro muChina, zvakaita sezviri kuShanghai neBeijing, zvine madhipatimendi epasi rose anobatsira varwere vekunze. Vanopa masevhisi akakwana anosanganisira kududzira, rubatsiro rwevhiza, uye zvirongwa zvekurapa zvakagadzirirwa. Iko kudhura-kushanda uye tekinoroji yepamusoro inoita kuti China ive nzvimbo inoyevedza yekushanya kwekurapa mune oncology.
Gore ra2026 rinoratidza nguva yakakosha munhoroondo ye kurapwa kenza yemapapu ekutanga. Kusangana kwehungwaru hwekugadzira, mushonga chaiwo, uye hunyanzvi hwekurapa kwashandura chaimbove mutongo werufu kuita chinhu chinogoneka, uye chinowanzorapika.
Kubva kuzvipatara zvine mutsindo zveShanghai kuenda kumakiriniki enharaunda akashongedzerwa neAI yekuongorora, nharaunda yezvekurapa yepasi rose yakabatana muchinangwa chayo chekuona gomarara remapapu nekukurumidza uye kurirapa zvakanyanya. Kudzikiswa kunoshamisa kwemitengo yekuongorora uye kuvapo kwekurapa kwakadzama senge maADC uye masoja ekudzivirira chirwere ane bispecific anopa tariro itsva kumamiriyoni.
Kune varwere nemhuri, meseji iri pachena: kuvhenekwa nekukurumidza kunoponesa hupenyu. Kugashira matekinoroji matsva uye kuomerera kugwara rekuongorora ndiwo matanho ane simba zvakanyanya anogona kutora. Sezvo tsvagiridzo irikuenderera mberi nekusundidzira miganhu, ramangwana rekuchengeta cancer yemapapu rinotaridzika kupenya kupfuura nakare kose, richivimbisa hupenyu hwakareba uye hupenyu huri nani kune vese vakabatwa.
Kunyangwe iwe uri kufunga sarudzo dzekuongorora, kuongorora nzvimbo dzekurapa, kana kutsvaga marapirwo ezvino, zviwanikwa uye kufambira mberi kunowanikwa muna 2026 zvinopa hwaro hwakasimba hwekurwisa chirwere ichi. Gara uchiziva, ita nekukurumidza, uye shandisa simba remushonga wechimanjemanje kuti uwane mhinduro yakanaka.